1-3 of 3
Jonathan W. Stocker, PhD
Close
Sort by
Journal Articles

SUSTAIN: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 with or without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises

Kenneth I. Ataga, MD, Abdullah Kutlar, MD, Julie Kanter, MD, Darla Liles, MD, Rodolfo Cancado, MD, PhD, João Friedrisch, MD PhD, Troy H. Guthrie, MD, Jennifer Knight-Madden, MBBS, PhD, Ofelia A. Alvarez, MD, Victor R. Gordeuk, MD, Sandra Gualandro, MD PhD, Marina Pereira Collela, MD PhD, Wally R. Smith, MD, Scott A. Rollins, PhD, Jonathan W. Stocker, PhD, Russell P. Rother, PhD
Journal: Blood
Blood (2016) 128 (22): 1.
https://doi.org/10.1182/blood.V128.22.1.1
Published: 2016
Journal Articles

Placebo-Controlled, Double-Blind, First-In-Human, Ascending Single Dose and Multiple Dose, Healthy Subject Study Of Intravenous-Administered SelG1, a Humanized Anti-P-Selectin Antibody In Development For Sickle Cell Disease

Jonathan W. Stocker, PhD, Debra Mandarino, MD, Ziad Kawar, PhD, Richard Alvarez, MBA, David Falconer, MS, MBA, Scott A. Rollins, PhD, Russell P. Rother, PhD
Journal: Blood
Blood (2013) 122 (21): 970.
https://doi.org/10.1182/blood.V122.21.970.970
Published: 2013
Journal Articles

A 48-Week Open-Label Study of Senicapoc (ICA-17043), a Gardos Channel Blocker, in Patients with Sickle Cell Disease.

Paul Swerdlow, MD, Kenneth Ataga, MD, Wally Smith, MD, Yogen Saunthararajah, MD, Jonathan W. Stocker, PhD
Journal: Blood
Blood (2006) 108 (11): 685.
https://doi.org/10.1182/blood.V108.11.685.685
Published: 2006